Evidence Based Medicine Examples. Edward G. Hamaty Jr., D.O. FACCP, FACOI. Meta Analysis & Diagnosis. Meta Analysis. Objectives
Edward G. Hamaty Jr., D.O. FACCP, FACOI
CAD Prevalence = 70.5%
Individual Curves Per/Wall
The administration of study drugs during PCI maintained the double-dummy, double-blind design (Fig. 1) (10).
The dose of study drug administered at PCI was determined by the time that had elapsed since administration of the last subcutaneous injection of study drug, and by whether concurrent glycoprotein (GP) IIb/IIIa inhibitors were to be used (Fig. 1).
Monitoring of the activated clotting time (ACT) during PCI was not recommended because standard doses of unfractionated heparin (UFH) were used, but the ACT could be measured at the discretion of the investigator, particularly if a clinical need arose.
Centers had the option of continuing study drug after a revascularization procedure, but this was not mandated by the study protocol.
Sheaths could be removed immediately after PCI if a vascular closure device was used or a radial artery procedure was performed or >6 h after the last injection of fondaparinux or enoxaparin.